Phase I/II Trial Evaluating Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung
The purpose of this study is to test whether 5 fraction stereotactic ablative body radiation (SABR) is safe and improves local control for early state squamous cell carcinoma of the lung.
The purpose of this study is to evaluate the amount of radiation used in stereotactic ablative ratiotherapy (SABR). This study asks if patients with non-small cell lung cancer of the lung squamous cell subtype can safely receive more radiation. If a higher radiation dose is found to be safe, the study then asks if that higher dose can control the cancer better than the current standard dose.
Participants will not be paid for their participation.
- IRB Number: 1706985235 (IUSCC-0624)
- Research Study Identifier: TX8196
- Principal Investigator: Tim Lautenschlaeger, MD